The first full week of November delivers a broad and high-impact earnings lineup across semiconductors, cloud software, AI, ...

Elsewhere, the busy earnings season continues with reports due from several notable companies such as Advanced Micro Devices, ...

A few years ago, Pfizer (NYSE: PFE) represented the ideal pharmaceutical stock investment. The company, as leader in the coronavirus vaccine and treatment market, offered a great deal of growth, and ...

Pfizer ($PFE) has filed a lawsuit in the Delaware Court of Chancery against Metsera ($MTSR), a U.S.-based obesity biotech ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and ...

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

I don’t know what to say about Pfizer. I mean, it’s got that yield of 7%. It bought that Seagen. I thought it was going to ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $30.0 for Pfizer during the past quarter. Looking at the volume ...

Pfizer Inc. (NYSE:PFE) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 27, Berenberg Bank ...